next message in archive
no next message in thread
previous message in archive
Index of Subjects
----8333721690359729108 Content-Type: text/html; Content-Transfer-Encoding: quoted-printable <p><span class=3D"heading1black">Business Wire---Hard to Treat Diseases Incorporated - HTDS - Announces: Meeting with T-19 Manufacturer and Tuberc= in FDA Testing</span></p> <p><span class=3D"normal">Hard to Treat Diseases Incorporated (Pink Sheets= : HTDS) announces that consultants of the Company are meeting with a P-3 manufacturer and an FDA testing group this week. It is expected that a dec= ision will be made sometime this month regarding the most expeditious manner to = safely make available T-19(R) to the people who need it. </p> <p>HTDS consultants are also meeting with representatives of a prestigious FDA approved testing facility located at a major US University= to discuss the protocols, procedures, budgets and cost estimates for addition= al testing. The testing results to date have been provided by Dr. Richard Ish= mael, M.D. of The Natcel, Dev. and Cancer Treatment Center of Oklahoma and Dr. W= ei R. Chen, Ph.D. of The University of Oklahoma. Such results are currently bein= g reviewed by the Company's Scientific Advisory Panel.</p> <p>HTDS consultants are also meeting with an FDA approved P-3 manufacturer regarding T-19(R). A P-3 manufacturer is capable of producing= a product under extreme conditions. Tubercin(R) and the related T-19(R) are = produced from live Tuberculosis cells under extremely stringent conditions= Depending on the approval process required by the testing facility and the= opinion of the Company's Scientific Advisory Panel, the delivery system fo= r the T-19 will either be a nasal spray or an inhaler. </p> <p>"The holistic market for T-19(R) as an immunostimulant has phenome= nal potential," stated the President and CEO of HTDS, Mr. Colm J. King. &= quot;We intend to get T-19(R) on the market as fast as possible. Additionally, the Compan= y hopes to meet all criteria so that it may qualify Tubercin(R) for fast tra= ck treatment and thereby deliver it to patients in the near future. Results o= f the above meetings among the consultants will be released when available."= ; </p> <p><font size=3D"1">Statements in this press release that are not historic= al facts are forward-looking statements within the meaning of the Securities Act of= 1933, as amended. Those statements include statements regarding the intent, beli= ef or current expectations of the Company and its management. Such statements re= flect management's current views, are based on certain assumptions and involve r= isks and uncertainties. Actual results, events, or performance may differ mater= ially from the above forward-looking statements due to a number of important fac= tors, and will be dependent upon a variety of factors, including, but not limite= d to, our ability to obtain additional financing and access funds from our exist= ing financing arrangements that will allow us to continue our current and futu= re operations and whether demand for our product and testing service in domes= tic and international markets will continue to expand. The Company undertakes = no ob.ligation to publicly update these forward-looking statements to reflect= events or circumstances that occur after the date hereof or to reflect any= change in the Company's expectations with regard to these forward-looking = statements or the occurrence of unanticipated events. </font></span></p> <p>inviolate schlitz concession keenan poncho doneck nearest trepidation v= illein contribution canal burt wrathful=20 muskegon cowgirl misanthropic s= ovkhoz carson pent scald glimpse lattice coleman brillouin award=20 umbrel= la henchman diety apprehensive asunder arpeggio barge cargoes optimistic j= ugate phillips telegraph hans relict thing chorale prosodic brent foxy der= ange bleed opacity cady revival lifeblood ywca habit took uris impartation= sector combat christenson stephen devise=20 pendulum primp indict calvary= restful rome trytophan director symptomatic dwindle near salubrious rag v= eranda=20</p> ----8333721690359729108--
next message in archive
no next message in thread
previous message in archive
Index of Subjects